The primary objective of the study is to determine if EMDR reduces the core symptoms of ASD and daily experienced stress in youngsters diagnosed with ASD.
ID
Source
Brief title
Condition
- Communication disorders and disturbances
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The main endpoint of the study are autism symptoms, which will be assessed
using the Social Responsiveness Scale (SRS-A) and the Autism Diagnostic
Observation Schedule (ADOS 2). The SRS-A will be administered prior, during and
after treatment. The ADOS 2 will be administered prior to treatment and after
treatment completion. In addition, we will also administer the Trauma Symptom
Investigation Form in Autism Spectrum Disorders (TIF-ASD) questionnaire prior
to, during, and after treatment.
Secondary outcome
To answer more fundamental questions concerning the working mechanism of EMDR
in ASD, other secondary outcome measures (i.e. Clinical Global Impression
Scales (CGI), Perceived Stress Scale-10 (PSS-10) en de Alloway Working Memory
Assessment (AWMA-2)) will be included.
Background summary
Currently, for youngsters there is no treatment available that directly targets
the core symptoms of autism. EMDR is hypothesized to improve the core symptoms
of ASD by reducing the generally high stress levels experienced during social
interactions, and increasing the functional connectivity in neuronal networks
associated with executive functioning and limbic circuitry.
Study objective
The primary objective of the study is to determine if EMDR reduces the core
symptoms of ASD and daily experienced stress in youngsters diagnosed with ASD.
Study design
Longitudinal multiple single case studies.
Intervention
Ten weekly EMDR sessions.
Study burden and risks
Participants are expected to benefit from treatment. The risks associated with
study participation are considered negligible and the burden associated with
participation is estimated as low.
Reinier Postlaan 12
Nijmegen 6525 GC
NL
Reinier Postlaan 12
Nijmegen 6525 GC
NL
Listed location countries
Age
Inclusion criteria
• Diagnosed with ASD (with or without comorbid psychiatric disorders, except PTSD and
anxiety disorders)
• Full-scale IQ of 80 or more
• 12-21 years of age
• Able to understand and speak Dutch
Exclusion criteria
• Youngsters exposed to other treatments than medication on a stable dosage
• Presence of PTSD or other comorbid psychiatric disorders that require immediate treatment
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL60026.091.16 |